Perspective
MiR-1246: A new link of the p53 family with cancer and Down syndrome
Purchase or Subscribe
Volume 11, Issue 14 July 15, 2012
Pages 2624 - 2630
http://dx.doi.org/10.4161/cc.20809
Keywords: DYRK1A, Down syndrome, NFAT, cancer, miR-1246, p53, tumorigenesis
Authors: Jun-Ming Liao, Xiang Zhou, Yu Zhang and Hua Lu
View affiliations Hide affiliations
- Jun-Ming Liao
-
Department of Biochemistry & Molecular Biology and Tulane Cancer Center; Tulane University School of Medicine; New Orleans, LA USA
- Xiang Zhou
-
Department of Biochemistry & Molecular Biology and Tulane Cancer Center; Tulane University School of Medicine; New Orleans, LA USA
- Yu Zhang
-
Department of Obstetrics and Gynecology; Xiangya Hospital; Central South University; Hunan, China
- Hua Lu
-
Corresponding author: hlu2@tulane.edu
Department of Biochemistry & Molecular Biology and Tulane Cancer Center; Tulane University School of Medicine; New Orleans, LA USA
Abstract:
Since the discovery of miRNAs, a number of miRNAs have been identified as p53’s transcriptional targets. Most of them are involved in regulation of the known p53 functions, such as cell cycle, apoptosis and senescence. Our recent study revealed miR-1246 as a novel target of p53 and its analogs p63 and p73 to suppress the expression of DYRK1A and consequently activate NFAT, both of which are associated with Down syndrome and possibly with tumorigenesis. This finding suggests that miR-1246 might serve as a likely link of the p53 family with Down syndrome. Here, we provide some prospective views on the potential role of the p53 family in Down syndrome via miR-1246 and propose a new p53-miR-1246-DYRK1A-NFAT pathway in cancer.
Received: April 10, 2012; Accepted: May 20, 2012
Preview:
Full Text - Ahead of Print Available - Log in!